MedTrace Logo

The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women

NCT01072097 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-09-07

No results posted yet for this study

Summary

This is a placebo controlled trial investigating the effect of 6 months atorvastatin 20mg/day therapy on androgens, glucose metabolism and inflammatory markers in women with PCOS.

We assume that during 6 months atorvastatin therapy a significant improvement in hyperandrogenism, glucose metabolism and inflammatory markers is observed.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Atorvastatin

Atorvastatin 20mg/day for 6 months

DRUG

Placebo

Placebo for 6 months

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Oulu

    lead OTHER

Principal Investigators

  • Terhi T. Piltonen, MD, PhD · Dept Ob-Gyn, University of Oulu

  • Johanna Puurunen, MD · Dept Ob-Gyn, University of Oulu

  • Juha S. Tapanainen, Professor · Dept Ob-Gyn, Univeristy of Oulu

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01072097 on ClinicalTrials.gov